143 related articles for article (PubMed ID: 6847139)
1. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients.
Jackson JA; Jankovic J; Ford J
Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
Jankovic J
Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
[TBL] [Abstract][Full Text] [Related]
3. Pergolide in late-stage Parkinson disease.
Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
[TBL] [Abstract][Full Text] [Related]
5. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.
Neophytides A; Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Bock J; Walker R
J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):261-3. PubMed ID: 7086448
[TBL] [Abstract][Full Text] [Related]
6. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
7. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Klawans HL; Paleologos N
Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575
[TBL] [Abstract][Full Text] [Related]
8. [Dopaminergic agonists in Parkinson disease].
Dubois B; Agid Y
Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
[No Abstract] [Full Text] [Related]
9. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
10. [Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy].
Yukitake M; Takashima Y; Kurohara K; Matsui M; Kuroda Y
Rinsho Shinkeigaku; 1996 Jul; 36(7):906-8. PubMed ID: 8952364
[TBL] [Abstract][Full Text] [Related]
11. [Clinical experience with bromocriptine, a central dopaminergic stimulator].
Ludin HP; Kunz F; Lörincz P; Ringwald E
Nervenarzt; 1976 Nov; 47(11):651-5. PubMed ID: 794749
[No Abstract] [Full Text] [Related]
12. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
[TBL] [Abstract][Full Text] [Related]
13. [A 65-year-old man with rigid-bradykinetic parkinsonism, vertical gaze palsy, difficulty of eye-lid opening, and marked pseudo-bulbar palsy].
Noda K; Kobayashi T; Matsuoka S; Takanashi M; Kanazawa A; Mizuno Y
No To Shinkei; 2005 Jan; 57(1):73-86. PubMed ID: 15782604
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pergolide and bromocriptine therapy in parkinsonism.
LeWitt PA; Ward CD; Larsen TA; Raphaelson MI; Newman RP; Foster N; Dambrosia JM; Calne DB
Neurology; 1983 Aug; 33(8):1009-14. PubMed ID: 6348585
[TBL] [Abstract][Full Text] [Related]
15. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
[TBL] [Abstract][Full Text] [Related]
16. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of progressive supranuclear palsy].
Finali G; Piccinin GL; Piccirilli M; Stefano E
Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956
[TBL] [Abstract][Full Text] [Related]
18. [A follow-up study on brainstem atrophy in progressive supranuclear palsy--when does brain MRI contribute to the differential diagnosis between progressive supranuclear palsy and Parkinson disease?].
Yamamoto T; Oya Y; Ogawa M; Ogata K; Kawai M
Rinsho Shinkeigaku; 2003 Jul; 43(7):392-7. PubMed ID: 14582364
[TBL] [Abstract][Full Text] [Related]
19. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.
Birdi S; Rajput AH; Fenton M; Donat JR; Rozdilsky B; Robinson C; Macaulay R; George D
Mov Disord; 2002 Nov; 17(6):1255-64. PubMed ID: 12465065
[TBL] [Abstract][Full Text] [Related]
20. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
